AbbVie and BigHat Biosciences announce research collaboration to leverage artificial intelligence and machine learning to discover next-generation therapeutic antibodies

AbbVie and BigHat Biosciences announce research collaboration to leverage artificial intelligence and machine learning to discover next-generation therapeutic antibodies

  • Collaboration to leverage BigHat’s artificial intelligence and machine learning (AI/ML), Milliner™ targeted platform, and AbbVie’s expertise in oncology and neuroscience to develop next-generation antibodies
  • BigHat to receive 30 million dollars Pay up front with the potential for more payouts and significant royalties

North Chicago, Illinois. And San Mateo, California., December 5, 2023 /PRNewswire/ — AbbVie Inc. announced… (NYSE: ABBV) and BigHat Biosciences today announced a research collaboration to discover and develop next-generation therapeutic antibodies in oncology and neuroscience. Working closely with AbbVie, BigHat will use its Milliner™ platform, a suite of machine learning technologies integrated with a high-speed wet lab, to guide the design and selection of high-quality antibodies for multiple therapeutic targets.

“This collaboration also demonstrates our commitment to integrating AI/ML-based approaches into drug discovery and development, as we strive to accelerate our oncology and neuroscience pipeline, and deliver better medicines faster,” he said. Jonathan Sedgwick, Ph.D., vice president and global head of discovery research at AbbVie. “We look forward to working with the BigHat team to design new antibody-based therapies that may help address the ongoing unmet needs that patients face.”

“We are pleased to collaborate with AbbVie, a global leader in driving innovation in drug development, and look forward to using our Milliner™ platform to help design the next generation of therapeutic antibodies,” he said. Mark DePristo, CEO of BigHat. “The Millliner™ software enables rapid optimization of several key parameters including functionality and scalability, to help deliver complex antibodies with improved properties more quickly.”

Under the terms of the agreement, BigHat will receive an upfront payment of 30 million dollars He may be eligible for up to approx $325 million In total R&D stages, with the potential to achieve further commercial milestones as well as tiered royalties on net sales.

About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve today’s serious health problems and address tomorrow’s medical challenges. We strive to make a significant impact on people’s lives across several key therapeutic areas – immunology, oncology, neuroscience and eye care – and the products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter)and YouTube.

About BigHat Biosciences
BigHat Biosciences designs safer and more effective biologic therapies for patients using machine learning and synthetic biology. BigHat combines a wet lab for high-speed characterization with machine learning techniques to guide the search for better antibodies. We apply these design capabilities to develop new generations of safer and more effective treatments for patients with today’s most challenging diseases.

BigHat is a Series B offshore biotech San Francisco With a team-oriented, inclusive and family-friendly culture. Our wholly owned and partnered pipeline of therapeutic programs focuses on indications with high unmet need, such as cancer and inflammation. It excited BigHat even more 100 million dollars Major investors include Section 32, a16z, and 8VC. To learn more about us, visit https://www.bighatbio.com And follow @BigHatBio on LinkedIn And Twitter.

Forward-looking statements
Certain statements in this press release are, or may be deemed to be, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project,” and similar expressions and uses forward-looking or conditional verbs, These generally identify forward-looking statements. AbbVie cautions that such forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or governmental actions, and changes in laws and regulations applicable to our industry. Additional information about economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is available in Item 1A, “Risk Factors” of AbbVie’s 2022 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. Stock Exchange Commission, as updated by its subsequent quarterly reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

Source: AbbVie

(Tags for translation)AbbVie

You may also like...

Leave a Reply